exenatide vs semaglutide GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management Emerging Therapies in Metabolic Health:

For example, in clinical trials of semaglutide 2.4 mg (Wegovy), nausea occurred in approximately 44% of patients, while rates for tirzepatide and other GLP-1s vary: Nausea : Often described as mild queasiness, particularly after eating, though some patients experience more pronounced nausea Bloating and abdominal fullness : A sensation of delayed digestion or food sitting heavily in the stomach Changes in bowel habits : Constipation affects approximately 15-30% of patients (varying by medication and dose), while some experience diarrhea or alternating patterns [1] [4] Decreased appetite : Beyond simple fullness, many report a fundamental shift in food thoughts, with reduced cravings and less mental preoccupation with eating Some patients report fatigue or low energy , particularly during the initial weeks

This is not dangerous but can feel intense

This may suggest that a subset of carriers may already exhibit early disease-associated changes despite not fulfilling current diagnostic criteria

Youdim, their benefits extend beyond weight loss, too

M., and Georgescu, E